9th Annual Biomarkers Congress

Pharmacology: Memorial Sloan-Kettering Cancer Center

Total Score People Score Events Score
28 26 7
Date Event Presentation Speakers
April 6, 2013 AACR Annual Meetings CANCER EVOLUTION AND RESISTANCE Neal Rosen
Cross-Species Analysis of Mouse and Human Cancer Chairperson: David J. Adams, Wellcome Trust Sanger Institute, Cambridge, United Kingdom Hans-Guido Wendel
Building on the Success of CTLA-4 Blockade Through Biomarker Analyses and Development of Novel Combinatorial Strategies Chairperson: Jedd D. Wolchok, Memorial Sloan-Kettering Cancer Center, New York, NY Jedd D. Wolchok, Margaret Callahan
Use of Next-Generation Sequencing: Implementation of Clinical Genomics Chairperson: David B. Solit, Memorial Sloan-Kettering Cancer Center, New York, NY David B. Solit
Structural Aberrations in a Thousand Tumors Chairperson: Raju Kucherlapati, Harvard Medical School, Boston, MA Chris Sander
The Molecular Basis for Improvement in Endometrial Cancer Therapy Co-Chairpersons: Cheryl Lyn Walker, Texas A&M University Health Science Center, Houston, TX, and Douglas A. Levine, Memorial Sloan-Kettering Cancer Center, New York, NY Douglas A. Levine
Using Genomics to Guide Cancer Immunotherapy Chairperson: Robert D. Schreiber, Washington University School of Medicine, St. Louis, MO James P Allison
Novel Therapeutic Concepts with Kinases, Immuno-, and Radiotherapy Chairperson: Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, NY James A. Fagin
Predictive Modeling of Cancer Treatment in Single Patients (N of 1) Moderator: Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, NY David B. Solit
Clinical Trials Based on Mutations versus Histology Charles L Sawyers
Credentialing Response Biomarkers for Signal Transduction Inhibitors Chairperson: Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY Neal Rosen
Noncoding RNAs in Cancer: From Pathogenesis to Therapeutics Chairperson: Elsa R. Flores, The University of Texas MD Anderson Cancer Center, Houston, TX Andrea Ventura
Tumor-Secreted Factors Chairperson: David C. Lyden, Weill Cornell Medical College of Cornell University, New York, NY David C Lyden
Progress in Targeting Chromatin Modifying Enzymes in Cancer Therapy Victoria M. Richon, Sanofi Oncology, Cambridge, MA Victoria M. Richon
Macrophages as a Therapeutic Target in the Tumor Microenvironment Johanna A. Joyce, Memorial Sloan-Kettering Cancer Center, New York, NY Johanna A. Joyce
September 13, 2011 The 22nd International Congress of the Society of Anesthesiologists Hall B | Non-Invasive Cardiac Output Monitoring (LP5) David Amar
Hall B | Cardiovascular Effects of Split Lung Ventilation and Pneumonectomy David Amar
February 24, 2011 Targeting P13K / mTOR Signaling in Cancer PI3K signaling and therapeutic response in gliomas Eric C Holland
Title to be announced Neal Rosen
February 13, 2011 Inositide Signaling in Pharmacology and Disease (X1) PI 3-Kinases (X2) | PI3K Pathways in Cancer, Mechanistic Insights Neal Rosen
October 20, 2010 6th Annual Meeting of the Oligonucleotide Therapeutics Society Control of 3´UTR length by alternative cleavage and polyadenylation and its role in human cancer Christine Mayr
May 30, 2008 ASCO Annual'08 Meeting general oncology sessions-- The Growing Challenge of CNS Metastases: New Therapeutic Approaches Lauren E. Abrey
general oncology sessions-- Integrating the Humanistic and Scientific Aspects of Patient Care: The Perspective of Seasoned Surgical, Medical, Pediatric, and Radiation Oncologists Teresa Gilewski
breast cancer-- Chemotherapy-Induced Cognitive Impairment (M06) Tim A Ahles
central nervous system tumors-- Chemotherapy-Induced Cognitive Impairment (M06) Tim A Ahles
central nervous system tumors-- The Growing Challenge of CNS Metastases: New Therapeutic Approaches Lauren E. Abrey
clinical trials-- Patient-Reported Outcomes in Oncology Ethan M. Basch
gynecologic cancer-- Benefit of Multimodality Management of Advanced Sarcoma: Why the Medical Oncologist Should Not Work Alone Murray F. Brennan
head and neck cancer-- Physiologic Response Imaging in Head and Neck Cancer Clifton Ling
health services research-- Patient-Reported Outcomes in Oncology Ethan M. Basch
lymphoma and plasma cell disorders-- Prognosis, Risk Stratification, and Treatment of Diffuse Large B-Cell Lymphoma: Incorporation of New Imaging Modalities and Molecular Markers (CPO11A) Andrew David Zelenetz
lymphoma and plasma cell disorders-- Prognosis, Risk Stratification, and Treatment of Diffuse Large B-Cell Lymphoma: Incorporation of New Imaging Modalities and Molecular Markers (CPO11B) Andrew David Zelenetz
patient and survivor care-- Patient-Reported Outcomes in Oncology Ethan M. Basch
patient and survivor care-- Integrating the Humanistic and Scientific Aspects of Patient Care: The Perspective of Seasoned Surgical, Medical, Pediatric, and Radiation Oncologists Teresa Gilewski
professional development-- Integrating the Humanistic and Scientific Aspects of Patient Care: The Perspective of Seasoned Surgical, Medical, Pediatric, and Radiation Oncologists Teresa Gilewski
sarcoma/bone and soft tissue cancers-- Benefit of Multimodality Management of Advanced Sarcoma: Why the Medical Oncologist Should Not Work Alone Murray F. Brennan
tumor biology-- Physiologic Response Imaging in Head and Neck Cancer Clifton Ling
meet the professor sessions-- Chemotherapy-Induced Cognitive Impairment (M06) Tim A Ahles
clinical problems in oncology-- Prognosis, Risk Stratification, and Treatment of Diffuse Large B-Cell Lymphoma: Incorporation of New Imaging Modalities and Molecular Markers (CPO11A) Andrew David Zelenetz
clinical problems in oncology-- Prognosis, Risk Stratification, and Treatment of Diffuse Large B-Cell Lymphoma: Incorporation of New Imaging Modalities and Molecular Markers (CPO11B) Andrew David Zelenetz
October 16, 2007 Inaugural HDAC inhibitors: Meeting the Challenges of Chemical Development of HDAC Inhibitors Oct (16 -17) OVERCOMING THE CHALLENGES: ADVANCED HDAC INHIBITORS (08:30-11:10) Paul A. Marks
OVERCOMING THE CHALLENGES - ADVANCED HDAC INHIBITORS: Chairperson’s Remarks (08:30-08:40) Paul A. Marks
MOLECULAR MODE-OF-ACTION AND BIOMARKER STRATEGIES FOR CLINICAL DEVELOPMENT: Histone Deacetylase Inhibitors: Molecular Mechanism of Action (11:10-11:40) Paul A. Marks
MOLECULAR MODE-OF-ACTION AND BIOMARKER STRATEGIES FOR CLINICAL DEVELOPMENT(11:10-16:30) Howard Scher, Paul A. Marks
MOLECULAR MODE-OF-ACTION AND BIOMARKER STRATEGIES FOR CLINICAL DEVELOPMENT: Panel Discussion- Are HDAC Inhibitors Proving Their Worth in the Clinic? (14:25-15:25) Howard Scher, Paul A. Marks
MOLECULAR MODE-OF-ACTION AND BIOMARKER STRATEGIES FOR CLINICAL DEVELOPMENT: Panel Chairperson’s Remarks (13:10-14:20) Paul A. Marks
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.